PLANO, Texas / Oct 23, 2024 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced it will release its third quarter 2024 operating results on Wednesday, October 30, 2024, after the close of the U.S. financial markets.
Management will host a conference call and webcast to discuss these financial results on Wednesday, October 30, 2024, at 5:00 p.m. ET. The presentation is open to all interested parties and may include forward-looking information.
Conference Call Details
Date/Time | Wednesday, October 30, 2024, at 5:00 p.m. ET | |
Webcast: | ||
U.S. Toll-Free Dial In: | 877-407-0890 | |
International Dial In: | +1-201-389-0918 |
To access the call, please dial in approximately ten minutes before the start of the call. For those unable to join the live call, an OnDemand version of the webcast will be available following the call under the URL link and on the investor relations website.
About Spok
Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Plano, Texas, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication.
Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.
| Last Trade: | US$13.19 |
| Daily Change: | -0.09 -0.68 |
| Daily Volume: | 107,072 |
| Market Cap: | US$271.710M |
October 29, 2025 July 30, 2025 April 30, 2025 February 26, 2025 October 30, 2024 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load